What Is Neulasta?

Pegfilgrastim, which is also known by the brand name, Neulasta, is a hematopoietic agent that is used to treat neutropenia. Neulasta was the first medication produced based on the active element pegfilgrastim.

Pegfilgrastim is not a hazardous drug, nor is it a form of chemotherapy. Several different biosimilars based on Neulasta have been produced to date.

Mechanism of Action

Pegfilgrastim is a blood cell colony-stimulating agent (CSA) and has been used successfully by cancer patients to stimulate the growth of white blood cells, more specifically neutrophils. It does this by stimulating the production of neutrophils directly from the bone marrow.

Precauții

Unless approved by your physician, pegfilgrastim is generally not recommended for:

• Patients who have an allergy to human granulocyte colony-stimulating factors (CFS) such as filgrastim or pegfilgrastim products. Allergic reactions can cause a rash over the whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using Neulasta, and call your doctor or get emergency help right away.
• Patients with sickle cell disorder. Using Neulasta can lead to a condition called sickle cell crisis, which may be life-threatening and require discontinuation of Neulasta.
• Patients receiving radiation therapy. Neulasta may increase the risk of developing a precancerous condition called myelodysplastic syndrome (MDS) or a type of blood cancer called acute myeloid leukemia (AML).

What To Avoid While Taking Pegfilgrastim

While on pegfilgrastim therapy, you must follow some precautions. Always tell your physician about any medication you are already taking. Do not take any drug or medicine (even herbals or over-the-counter medications) without prior consent from your physician or pharmacist, as they may have interactions with Neulasta. Avoid taking Neulasta within 14 days before or 24 hours after having chemotherapy.